CLINICAL_TRIALS
trial_result
· 2013-05-27
Clinical Trial Update: Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen [Phase 2]
Summary
Phase 2 safety and immunogenicity study of GSK's malaria vaccine 257049 when incorporated into an EPI regimen completed; results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2013-05-27